KR20010101732A - 알키닐 함유 히드록삼산 유도체, 이의 제조 및 매트릭스메탈로프로테이나제(엠엠피) 억제제/티엔에프-알파 전환효소(티에이씨이이)억제제로서의 이의 용도 - Google Patents

알키닐 함유 히드록삼산 유도체, 이의 제조 및 매트릭스메탈로프로테이나제(엠엠피) 억제제/티엔에프-알파 전환효소(티에이씨이이)억제제로서의 이의 용도 Download PDF

Info

Publication number
KR20010101732A
KR20010101732A KR1020017009432A KR20017009432A KR20010101732A KR 20010101732 A KR20010101732 A KR 20010101732A KR 1020017009432 A KR1020017009432 A KR 1020017009432A KR 20017009432 A KR20017009432 A KR 20017009432A KR 20010101732 A KR20010101732 A KR 20010101732A
Authority
KR
South Korea
Prior art keywords
methyl
phenyl
sulfonyl
piperidine
hydroxy
Prior art date
Application number
KR1020017009432A
Other languages
English (en)
Korean (ko)
Inventor
레빈제레미이안
벤카터산아라나파캄머둠바이
첸제임스밍
자스크아리에
산다나야카빈센트프리마라나
듀밀라티
베이커제니리아
Original Assignee
윌리암 에이취 캘넌, 에곤 이 버그
아메리칸사이아나미드컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 에이취 캘넌, 에곤 이 버그, 아메리칸사이아나미드컴파니 filed Critical 윌리암 에이취 캘넌, 에곤 이 버그
Priority claimed from PCT/US2000/001864 external-priority patent/WO2000044723A1/en
Publication of KR20010101732A publication Critical patent/KR20010101732A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020017009432A 1999-01-27 2000-01-27 알키닐 함유 히드록삼산 유도체, 이의 제조 및 매트릭스메탈로프로테이나제(엠엠피) 억제제/티엔에프-알파 전환효소(티에이씨이이)억제제로서의 이의 용도 KR20010101732A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23803899A 1999-01-27 1999-01-27
US09/238,038 1999-01-27
PCT/US2000/001864 WO2000044723A1 (en) 1999-01-27 2000-01-27 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors

Publications (1)

Publication Number Publication Date
KR20010101732A true KR20010101732A (ko) 2001-11-14

Family

ID=22896246

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009432A KR20010101732A (ko) 1999-01-27 2000-01-27 알키닐 함유 히드록삼산 유도체, 이의 제조 및 매트릭스메탈로프로테이나제(엠엠피) 억제제/티엔에프-알파 전환효소(티에이씨이이)억제제로서의 이의 용도

Country Status (13)

Country Link
JP (1) JP2002535390A (xx)
KR (1) KR20010101732A (xx)
AR (1) AR035312A1 (xx)
AT (1) ATE309986T1 (xx)
AU (1) AU769418B2 (xx)
CA (1) CA2356313A1 (xx)
CZ (1) CZ20012711A3 (xx)
DE (1) DE60024056D1 (xx)
EA (1) EA200100806A1 (xx)
HU (1) HUP0200223A3 (xx)
IL (1) IL144345A0 (xx)
NZ (1) NZ512566A (xx)
ZA (1) ZA200105222B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4566006B2 (ja) * 2002-12-26 2010-10-20 カルナバイオサイエンス株式会社 アルキニル基置換アザ糖誘導体およびそれを有効成分とする薬剤
CA2656398A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AU2009254959B2 (en) * 2008-06-02 2014-01-30 Cipla Limited Processes for the synthesis of levocetirizine and intermediates for use therein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT970046E (pt) * 1997-02-27 2004-04-30 Wyeth Corp N-hidroxi-2-(alquil, aril, ou heteroaril sulfanil, sulfinil ou sulfonil)-alquil, aril ou heteroaril amidas substituidas em 3 como inibidores de metaloproteinase de matriz
EP1054858A1 (en) * 1998-02-19 2000-11-29 American Cyanamid Company N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
NZ512566A (en) 2004-02-27
CA2356313A1 (en) 2000-08-03
DE60024056D1 (de) 2005-12-22
CZ20012711A3 (cs) 2002-05-15
AR035312A1 (es) 2004-05-12
JP2002535390A (ja) 2002-10-22
ZA200105222B (en) 2002-09-25
IL144345A0 (en) 2002-05-23
ATE309986T1 (de) 2005-12-15
AU769418B2 (en) 2004-01-29
AU2630500A (en) 2000-08-18
HUP0200223A3 (en) 2002-12-28
EA200100806A1 (ru) 2002-08-29
HUP0200223A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
AU775701B2 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
AU730127B2 (en) Sulfamide-metalloprotease inhibitors
EP1147085B1 (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
JP2000510162A (ja) アリールスルホニルヒドロキサム酸誘導体
MXPA02009312A (es) Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas.
NO314302B1 (no) Matriksmetalloproteinase-inhibitorer, anvendelse derav samt farmasöytisk blanding
CA2416384A1 (en) Sulfone derivatives, their production and use
PL198032B1 (pl) Pochodne amidów, sposób ich wytwarzania, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
JP2004513063A (ja) 細胞接着阻害抗炎症および免疫抑制化合物
US20020099035A1 (en) Method for preparing alpha-sulfonyl hydroxamic acid derivatives
JP2003520852A (ja) α−スルホニルヒドロキサム酸誘導体を製造する方法
US6753337B2 (en) Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
KR20010101732A (ko) 알키닐 함유 히드록삼산 유도체, 이의 제조 및 매트릭스메탈로프로테이나제(엠엠피) 억제제/티엔에프-알파 전환효소(티에이씨이이)억제제로서의 이의 용도
JP2002201178A (ja) スルホン誘導体、その製造法及び用途
MXPA01007573A (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
CZ255199A3 (cs) Derivát sulfamidu inhibující metaloproteázu, způsob jeho přípravy a jeho použití pro výrobu léčiv

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid